Protocol Ledger

NCT04567420 · Phase II · ACTIVE NOT RECRUITING

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Interventional Phase II clinical trial protocol NCT04567420 sponsored by Criterium in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-02-09 Enrollment: 70 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04567420
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)70 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04567420
Protocol FieldVerified Registry Value
NCT IdentifierNCT04567420
Consolidated Lead SponsorCriterium
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment70 participants (ESTIMATED)
Registered Start Date2021-02-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI